The purpose of the project is to set up a national, prospective, longitudinal, multicenter registry platform to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with hematological malignancies in Germany.
RUBIN is a national, observational, prospective, longitudinal, multicenter registry platform with the purpose to record information on the antineoplastic treatment of hematological malignancies in Germany. It will identify common therapeutic sequences and changes in the treatment of the disease, and will analyse the impact of novel treatments on the outcome of patients in routine care. Unmet needs and areas with the potential for improvement in routine care are to be identified. At inclusion, data in patient characteristics, comorbidities, clinical characteristics and previous treatments, if applicable, are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and clinical outcome are documented. Health-realted quality of life in patients with hematological malignancies will be evaluated for up to one year.
Study Type
OBSERVATIONAL
Enrollment
2,950
Physician's choice according to patient's needs.
Praxis für Interdisziplinäre Hämatologie und Onkologie
Freiburg im Breisgau, Germany
RECRUITINGCourse of treatment (treatment reality)
Documentation of anamnestic data and therapy sequences. Documentation of anamnestic data and therapy sequences
Time frame: 5 years
Best Response
Documentation of response rates per line of treatment.
Time frame: 5 years
Progression-free survival
Documentation of progression-free survival per line of treatment.
Time frame: 5 years
Overall survival
Documentation of overall survival time.
Time frame: 5 years
Health-related quality of life (Patient-reported outcome)
EORTC QLQ-C30 core questionnaire
Time frame: 1 year
Disease-specific quality of life (Patient-reported outcome, patients with CLL)
EORTC QLQ-CLL17
Time frame: 1 year
Disease-specific quality of life (Patient-reported outcome, patients with LG-NHL)
EORTC QLQ-NHL-LG20
Time frame: 1 year
Disease-specific quality of life (Patient-reported outcome, patients with HG-NHL)
EORTC QLQ-NHL-HG29
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.